Legal Representation
Attorney
Lisa Greenwald-Swire
USPTO Deadlines
Next Deadline
46 days remaining
Statement of Use Due - Extension 2 Granted
Due Date
September 05, 2025
Extension Available
Until March 05, 2025
Application History
31 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 2, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 1, 2025 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Jun 24, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Mar 17, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Mar 17, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Mar 17, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Mar 5, 2025 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Mar 4, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 3, 2025 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Sep 5, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Sep 5, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Sep 5, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Sep 5, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 5, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jan 9, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jan 9, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 20, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Dec 2, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 2, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Dec 2, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 2, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 2, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Nov 28, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 27, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Nov 27, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 29, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 29, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 29, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 29, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 8, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 19, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Biological preparations for scientific use for use in gene therapy, gene editing, gene insertion, and cell therapy
Class 005
Pharmaceutical preparations and biological preparations for medical treatment for use in gene therapy, gene editing, gene insertion, and cell therapy for the treatment of genetic disorders; Pharmaceutical and biological preparations for the treatment of genetic disorders; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, modification, regulation, and repair for use in human therapeutics
Class 042
Medical and scientific research; Medical research and development in the fields of genomic medicine, genome engineering, and cell engineering; Scientific research and development in the field of genomic medicine, genome engineering, and cell engineering; Research and development of pharmaceutical preparations for gene therapy, gene editing, gene insertion, and cell therapy; Providing medical and scientific research information in the fields of genomic medicine, genome engineering, and cell engineering
Class 044
Providing medical and healthcare information in the field of gene sequencing, gene editing, and gene insertion technologies; Providing medical and healthcare information regarding gene therapies and cell therapies
Classification
International Classes
001
005
042
044